Pharmacokinetic study of crizotinib in Japanese patients with ALK fusion gene positive Non-small cell carcinoma
Phase of Trial: Phase II
Latest Information Update: 07 Jun 2017
Price : $35 *
At a glance
- Drugs Crizotinib (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
- 31 Jul 2016 Status changed from active, no longer recruiting to completed.
- 27 Feb 2013 Status changed from not yet recruiting to recruiting as reported by University Hospital Medical Information Network - Japan record.
- 12 Feb 2013 New trial record